CIM
NTLA icon

CIM Investment Management’s Intellia Therapeutics NTLA Stock Holding History

CIM Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,721
Closed -$203K – 285
2021
Q4 		$203K Buy
+1,721
New +$216K 0.06% 289
2019
Q2 		– Sell
-21,546
Closed -$368K – 336
2019
Q1 		$368K Sell
21,546
-183
-0.8% -$2.73K 0.14% 191
2018
Q4 		$297K Hold
21,729
– – 0.13% 210
2018
Q3 		$622K Hold
21,729
– – 0.22% 101
2018
Q2 		$595K Hold
21,729
– – 0.21% 126
2018
Q1 		$458K Buy
+21,729
New +$534K 0.16% 186

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CIM Investment Management's NTLA Position: Q1 2022 in Review

CIM Investment Management sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 1,721 shares — an estimated $203K sold.

CIM Investment Management first reported a position in NTLA in Q1 2018 and held it in 6 quarters. The position peaked at $622K in Q3 2018. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

  • CIM Investment Management reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
  • CIM Investment Management sold 1,721 Intellia Therapeutics shares in Q1 2022, an estimated $203K.
  • CIM Investment Management first reported a position in Intellia Therapeutics in Q1 2018 and held it in 6 quarters.
  • CIM Investment Management's Intellia Therapeutics position peaked at $622K in Q3 2018.
  • 348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on CIM Investment Management's 13F filing for Q1 2022, filed 17 May 2022.